2620 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Pooled anti-VEGF cohort subanalysis. (September 2015) - Alekseev, B.; Yang, L.; Alyasova, A.; Ye, D.; Karpenko, A.; Li, H.; Xie, L.; Kurteva, G.; Kowalyszyn, R.; Karyakin, O.; Neron, Y.; Cosgriff, T.; et al.